Abstract | OBJECTIVE: METHODS:
EMMPRIN expression was semiquantified by immunohistochemistry with anti-human EMMPRIN monoclonal antibody in 208 surgically resected NSCLCs and was analyzed statistically in relation to various characteristics. RESULTS:
EMMPRIN expression was seen in most NSCLC samples (92%). High levels of EMMPRIN expression were significantly associated with differentiation and pT(1) stage in adenocarcinomas. There were no significant differences in overall survival between patients with tumors having high and low levels of EMMPRIN expression in pathological stage I NSCLCs (5-year survival rates, 69 vs. 60%). CONCLUSIONS:
EMMPRIN was preferentially expressed in most NSCLCs. High levels of expression were associated with early T stage and well-differentiated adenocarcinoma, and were not a prognostic factor in NSCLC.
|
Authors | Nobuyuki Hakuma, Tomoko Betsuyaku, Ichiro Kinoshita, Tomoo Itoh, Kichizo Kaga, Satoshi Kondo, Masaharu Nishimura, Hirotoshi Dosaka-Akita |
Journal | Oncology
(Oncology)
Vol. 72
Issue 3-4
Pg. 197-204
( 2007)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 18160808
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | (c) 2007 S. Karger AG, Basel |
Chemical References |
|
Topics |
- Aged
- Basigin
(biosynthesis)
- Carcinoma, Non-Small-Cell Lung
(metabolism, pathology, surgery)
- Female
- Humans
- Immunohistochemistry
- Lung Neoplasms
(metabolism, pathology, surgery)
- Male
- Middle Aged
- Prognosis
|